Neuro-oncology clinical trials: Promise and pitfalls

被引：5

作者：

Gilbert, MR ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2001年 / 12卷 / 02期

关键词：

D O I：

10.1093/oxfordjournals.annonc.a000239

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：149 / 150

页数：2

共 18 条

[1] Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse [J].

Brada, M ;

Hoang-Xuan, K ;

Rampling, R ;

Dietrich, PY ;

Dirix, LY ;

Macdonald, D ;

Heimans, JJ ;

Zonnenberg, BA ;

Bravo-Marques, JM ;

Henriksson, R ;

Stupp, R ;

Yue, N ;

Bruner, J ;

Dugan, M ;

Rao, S ;

Zaknoen, S .

ANNALS OF ONCOLOGY, 2001, 12 (02) :259-266

[2] Temozolomide as a second-line systemic regimen in recurrent high-grade glioma:: A phase II study [J].

Brandes, AA ;

Ermani, M ;

Basso, U ;

Amistà, P ;

Berti, F ;

Scienza, R ;

Rotilio, A ;

Pinna, G ;

Gardiman, M ;

Monfardini, S .

ANNALS OF ONCOLOGY, 2001, 12 (02) :255-257

[3] Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases [J].

Christodoulou, C ;

Bafaloukos, D ;

Kosmidis, P ;

Samantas, E ;

Bamias, A ;

Papakostas, P ;

Karabelis, A ;

Bacoyiannis, C ;

Skarlos, DV .

ANNALS OF ONCOLOGY, 2001, 12 (02) :249-254

[4] RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORS IN 3 RADIATION-THERAPY ONCOLOGY GROUP MALIGNANT GLIOMA TRIALS [J].

CURRAN, WJ ;

SCOTT, CB ;

HORTON, J ;

NELSON, JS ;

WEINSTEIN, AS ;

FISCHBACH, AJ ;

CHANG, CH ;

ROTMAN, M ;

ASBELL, SO ;

KRISCH, RE ;

NELSON, DF .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (09) :704-710

[5] Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions [J].

Fetell, MR ;

Grossman, SA ;

Fisher, JD ;

Erlanger, B ;

Rowinsky, E ;

Stockel, J ;

Piantadosi, S .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3121-3128

[6]

Franciosi V, 1999, CANCER, V85, P1599, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.3.CO

[7]

2-R

[8]

Friedman HS, 2000, CLIN CANCER RES, V6, P2585

[9] Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants [J].

Grossman, SA ;

Hochberg, F ;

Fisher, J ;

Chen, TL ;

Kim, L ;

Gregory, R ;

Grochow, LB ;

Piantadosi, S .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (02) :118-126

[10]

GROVES MD, 2000, NEURO-ONCOLOGY, V2, P266

← 1 2 →